SCHEMBL4853701

SCHEMBL4853701

CCCCCC(/C=C/c1ccc(C(=O)OC)cc1)c1ccc2c(c1)N(C(=O)OC(C)(C)C)CCC2(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
RARB P10826 7/20 0.35
RARA P10276 6/20 0.35
RARG P13631 5/20 0.35
PKM P14618 1/20 0.34
KDM1A O60341 1/20 0.34
CYP3A4 P08684 3/20 0.33
NR1H2 P55055 1/20 0.32
KDM4D Q6B0I6 1/20 0.32
PDE4A P27815 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32
CYP26A1 O43174 2/20 0.31
CNR1 P21554 1/20 0.31
CNR2 P34972 1/20 0.31
ITGB3 P05106 1/20 0.31
ITGA2B P08514 1/20 0.31
SLC6A2 P23975 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4853709 1.00 HDAC1 (0.39) HDAC1HDAC6RARBRARARARG
SCHEMBL4853714 1.00 HDAC1 (0.39) HDAC1HDAC6RARBRARARARG
SCHEMBL27530878 0.90 RARB (0.40) RARBRARARARGCYP3A4CYP26A1
SCHEMBL4847176 0.86 RARB (0.41) RARBRARARARGCYP3A4CYP26A1
SCHEMBL4847182 0.86 RARB (0.41) RARBRARARARGCYP3A4CYP26A1
SCHEMBL4848678 0.84 KDM1A (0.40) HDAC1HDAC6RARBRARGKDM1A
SCHEMBL4847633 0.82 HDAC1 (0.39) HDAC1HDAC6RARBRARARARG
SCHEMBL4850254 0.81 KDM1A (0.38) RARBRARGKDM1APDE4APDE4B
SCHEMBL6146573 0.81 RARA (0.52) RARBRARARARGCYP3A4CYP26A1
SCHEMBL6144236 0.79 RARB (0.53) RARBRARARARGCYP3A4CYP26A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7354931-B2 Treating obstructive airway disorders using nontoxic drug ROCHE PALO ALTO LLC (US) 2008-04-08 US disclosed
EP-1442032-B1 HETEROCYCLIC RETINOID COMPOUNDS HOFFMANN LA ROCHE (CH) 2007-04-18 EP disclosed
US-20050049238-A1 Heterocyclic retinoid compounds KLAUS MICHAEL (DE) 2005-03-03 US disclosed
US-6818652-B2 THERAPEUTIC TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, CANCER AND DERMATOLOGICAL SKIN DISORDERS SYNTEX (U.S.A.) LLC 2004-11-16 US disclosed
EP-1442032-A1 HETEROCYCLIC RETINOID COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2004-08-04 EP disclosed
US-20030158178-A1 Heterocyclic retinoid compounds SYNTEX (U.S.A.) LLC 2003-08-21 US disclosed
WO-2003037882-A1 HETEROCYCLIC RETINOID COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2003-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049238-A1 Heterocyclic retinoid compounds RARG, RXRG, RXRA HDAC1 486/4885HDAC6 526/4885RARB 5/4885
US-20030158178-A1 Heterocyclic retinoid compounds RARG, RXRG, RXRA HDAC1 486/4885HDAC6 526/4885RARB 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.